These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 12131543)

  • 21. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study.
    Bella JN; Wachtell K; Palmieri V; Liebson PR; Gerdts E; Ylitalo A; Koren MJ; Pedersen OL; Rokkedal J; Dahlöf B; Roman MJ; Devereux RB
    J Hypertens; 2001 Jan; 19(1):127-34. PubMed ID: 11204292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy.
    Gerdts E; Okin PM; Boman K; Wachtell K; Nieminen MS; Dahlöf B; Devereux RB
    Am J Hypertens; 2012 Jun; 25(6):678-83. PubMed ID: 22456225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
    Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
    J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B;
    Ann Intern Med; 2007 Sep; 147(5):311-9. PubMed ID: 17785486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
    Dahlöf B; Devereux RB; Julius S; Kjeldsen SE; Beevers G; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Hypertension; 1998 Dec; 32(6):989-97. PubMed ID: 9856962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
    Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
    Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
    Gerdts E; Roman MJ; Palmieri V; Wachtell K; Smith G; Nieminen MS; Dahlöf B; Devereux RB
    J Hum Hypertens; 2004 Jun; 18(6):417-22. PubMed ID: 15103312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
    Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint.
    Wachtell K; Smith G; Gerdts E; Dahlöf B; Nieminen MS; Papademetriou V; Bella JN; Ibsen H; Rokkedal J; Devereux RB
    Am J Cardiol; 2000 Feb; 85(4):466-72. PubMed ID: 10728952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation.
    Okin PM; Gerdts E; Wachtell K; Oikarinen L; Nieminen MS; Dahlöf B; Devereux RB
    J Hypertens; 2010 Jul; 28(7):1534-40. PubMed ID: 20589977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
    Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Dahlöf B;
    Circulation; 2006 Jan; 113(1):67-73. PubMed ID: 16365195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Echocardiographic Left Ventricular Reverse Remodeling After 18 Months of Antihypertensive Treatment in Stage I Hypertension. Results From the Prever-Treatment Study.
    Bertoluci C; Foppa M; Santos ABS; Branchi TV; Fuchs SC; Fuchs FD
    Am J Hypertens; 2018 Feb; 31(3):321-328. PubMed ID: 29036504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of left ventricular mass change during treatment of hypertension.
    Devereux RB; Wachtell K; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris K; Aurup P; Dahlöf B
    JAMA; 2004 Nov; 292(19):2350-6. PubMed ID: 15547162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
    Palmieri V; Okin PM; de Simone G; Bella JN; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    J Hypertens; 2007 May; 25(5):1079-85. PubMed ID: 17414673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of achieved systolic blood pressure on renal function in hypertensive patients.
    Okin PM; Kjeldsen SE; Devereux RB
    Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):271-276. PubMed ID: 29474712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cornell product in an electrocardiogram is related to reduced LV regional wall motion.
    Ishikawa J; Yamanaka Y; Watanabe S; Toba A; Harada K
    Hypertens Res; 2019 Apr; 42(4):541-548. PubMed ID: 30542082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
    Larstorp AC; Ariansen I; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Dahlöf B; Kjeldsen SE; Wachtell K
    Hypertension; 2012 Aug; 60(2):347-53. PubMed ID: 22753219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.